Golden Throat Holdings Group Company Limited (HKG:6896)
Hong Kong
· Delayed Price · Currency is HKD 4.480
-0.060 (-1.32%)
Jun 17, 2025, 4:08 PM HKT
HKG:6896 Revenue
In the year 2024, Golden Throat Holdings Group Company had annual revenue of 1.19B CNY with 23.26% growth. Golden Throat Holdings Group Company had revenue of 660.49M in the half year ending December 31, 2024, a decrease of -2.86%.
Revenue
1.19B CNY
Revenue Growth
+23.26%
P/S Ratio
2.66
Revenue / Employee
1.36M CNY
Employees
874
Market Cap
3.36B HKD
Revenue Chart
* This company reports financials in CNY.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 1.19B | 223.63M | 23.26% |
| Dec 31, 2023 | 961.38M | -30.64M | -3.09% |
| Dec 31, 2022 | 992.01M | 171.47M | 20.90% |
| Dec 31, 2021 | 820.54M | 173.60M | 26.83% |
| Dec 31, 2020 | 646.94M | -150.19M | -18.84% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeOne Medicines | 32.49B |
| Hansoh Pharmaceutical Group Company | 13.05B |
| Innovent Biologics | 10.03B |
| JD Health International | 61.89B |
| WuXi Biologics | 19.87B |
| CSPC Pharmaceutical Group | 28.99B |
| Sino Biopharmaceutical | 30.72B |
| Akeso | 2.26B |